Thus, further research is warranted in the context of using in vivo models to evaluate whether modulation of LARS1 expression by LARS1 overexpression or LARS1 knockdown can reverse PGC-1α actions on tumor progression. The gene discussed is LARS1; the disease is neoplasm.